Joan H. Schiller
Experienced in Ovarian Cancer

Dr. Joan H. Schiller

Hematology Oncology
Dallas, TX 
Clinical Trials:Currently Recruiting for 1 Trial
42 Years of Experience
Experienced in Ovarian Cancer
Dallas, TX 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Joan Schiller is a Hematologist Oncology provider in Dallas, Texas. Dr. Schiller has been practicing medicine for over 42 years and is rated as an Experienced provider by MediFind in the treatment of Ovarian Cancer. Her top areas of expertise are Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Lung Adenocarcinoma, and Small Cell Lung Cancer (SCLC).

Her clinical research consists of co-authoring 92 peer reviewed articles and participating in 8 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 1 article in the study of Ovarian Cancer.

Specialties
Hematology Oncology
Licenses
Internal Medicine in TX
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO

Locations

Dallas, TX 75390

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

8 Clinical Trials

A Randomized Phase III Trial for Surgically Resected Early Stage Non-small Cell Lung Cancer: Crizotinib Versus Observation for Patients With Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein
A Randomized Phase III Trial for Surgically Resected Early Stage Non-small Cell Lung Cancer: Crizotinib Versus Observation for Patients With Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein
Enrollment Status: Recruiting
Publish Date: July 03, 2024
Intervention Type: Other, Drug
Study Drug: Crizotinib
Study Phase: Phase 3
Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
Enrollment Status: Active_not_recruiting
Publish Date: December 17, 2025
Intervention Type: Other, Procedure, Biological, Drug
Study Phase: Not Applicable
Randomized Study of Erlotinib Vs Observation in Patients With Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)
Randomized Study of Erlotinib Vs Observation in Patients With Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)
Enrollment Status: Active_not_recruiting
Publish Date: December 04, 2025
Intervention Type: Other, Drug
Study Drug: Erlotinib Hydrochloride
Study Phase: Phase 3
Adjuvant Nivolumab in Resected Lung Cancers (ANVIL)-A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers
Adjuvant Nivolumab in Resected Lung Cancers (ANVIL)-A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers
Enrollment Status: Active_not_recruiting
Publish Date: November 17, 2025
Intervention Type: Procedure, Biological, Other
Study Drug: Nivolumab
Study Phase: Phase 3
Phase 3 Randomized Study Comparing X-396 (Ensartinib) to Crizotinib in Anaplastic Lymphoma Kinase (ALK) Positive Non-Small Cell Lung Cancer (NSCLC) Patients
Phase 3 Randomized Study Comparing X-396 (Ensartinib) to Crizotinib in Anaplastic Lymphoma Kinase (ALK) Positive Non-Small Cell Lung Cancer (NSCLC) Patients
Enrollment Status: Active_not_recruiting
Publish Date: October 14, 2025
Intervention Type: Drug
Study Drugs: X-396 (Ensartinib), Crizotinib
Study Phase: Phase 3
Randomized, Double Blinded Phase III Trial of Cisplatin and Etoposide Plus Thoracic Radiation Therapy Followed By Nivolumab/Placebo For Locally Advanced Non-Small Cell Lung Cancer
Randomized, Double Blinded Phase III Trial of Cisplatin and Etoposide Plus Thoracic Radiation Therapy Followed By Nivolumab/Placebo For Locally Advanced Non-Small Cell Lung Cancer
Enrollment Status: Terminated
Publish Date: June 02, 2021
Intervention Type: Radiation, Other, Drug
Study Phase: Phase 3
An Open-label, Multi-center, Expanded Treatment Protocol (ETP) of Oral LDK378 in Adult Patients With Non-small Cell Lung Cancer (NSCLC) Characterized by ALK Positivity
An Open-label, Multi-center, Expanded Treatment Protocol (ETP) of Oral LDK378 in Adult Patients With Non-small Cell Lung Cancer (NSCLC) Characterized by ALK Positivity
Enrollment Status: No_longer_available
Publish Date: November 03, 2020
Intervention Type: Drug
Randomized, Phase II, Open-Label Controlled Study of Two Different Doses and Schedules of EMD 72000 (Matuzumab) in Combination With Pemetrexed, or Pemetrexed Alone, as Second-Line Treatment for Stage IIIB/IV Non-Small Cell Lung Cancer and Progressive Disease on or After First-Line Treatment With a Platinum in Combination With Taxanes, Gemcitabine and Vinorelbine
Randomized, Phase II, Open-Label Controlled Study of Two Different Doses and Schedules of EMD 72000 (Matuzumab) in Combination With Pemetrexed, or Pemetrexed Alone, as Second-Line Treatment for Stage IIIB/IV Non-Small Cell Lung Cancer and Progressive Disease on or After First-Line Treatment With a Platinum in Combination With Taxanes, Gemcitabine and Vinorelbine
Enrollment Status: Completed
Publish Date: April 06, 2018
Intervention Type: Drug
Study Phase: Phase 2
View 7 Less Clinical Trials

92 Total Publications

Embracing Compassion for People Facing Lung Cancer-The American Cancer Society National Lung Cancer Roundtable.
Embracing Compassion for People Facing Lung Cancer-The American Cancer Society National Lung Cancer Roundtable.
Journal: Annals of internal medicine
Published: June 02, 2025
Similar Doctors
Advanced in Ovarian Cancer
Dr. Kathleen M. Crowley
Hematology Oncology | Hematology | Oncology
Advanced in Ovarian Cancer
Dr. Kathleen M. Crowley
Hematology Oncology | Hematology | Oncology

Acclaim Physician Group Inc

1201 S Main St, 
Fort Worth, TX 
 (28.7 miles away)
817-702-6500
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Kathleen Crowley is a Hematologist Oncology specialist and a Hematologist in Fort Worth, Texas. Dr. Crowley is rated as a Distinguished provider by MediFind in the treatment of Ovarian Cancer. Her top areas of expertise are Sickle Cell Disease, Ovarian Carcinosarcoma, Sertoli-Leydig Cell Tumor, and Cervical Cancer. Dr. Crowley is currently accepting new patients.

Advanced in Ovarian Cancer
Dr. Prasanthi Ganesa
Hematology Oncology | Oncology
Advanced in Ovarian Cancer
Dr. Prasanthi Ganesa
Hematology Oncology | Oncology

Oncology-Hematology Consultants PA

6100 Harris Pkwy, Suite 235, 
Fort Worth, TX 
 (35.4 miles away)
817-759-7000
Languages Spoken:
English, Hindi, Taiwanese, Tamil, Telugu, Urdu
See accepted insurances
Accepting New Patients

Prasanthi Ganesa is a Hematologist Oncology specialist and an Oncologist in Fort Worth, Texas. Dr. Ganesa is rated as an Advanced provider by MediFind in the treatment of Ovarian Cancer. Her top areas of expertise are Paget Disease of the Breast, Breast Cancer, Pleuropulmonary Blastoma, and HER-2 Positive Breast Cancer. Dr. Ganesa is currently accepting new patients.

Experienced in Ovarian Cancer
Dr. Henry H. Xiong
Hematology Oncology | Oncology
Experienced in Ovarian Cancer
Dr. Henry H. Xiong
Hematology Oncology | Oncology

Oncology-Hematology Consultants PA

800 W Magnolia Ave, 
Fort Worth, TX 
 (29.2 miles away)
Languages Spoken:
English, Hindi, Mandarin, Spanish, Taiwanese, Urdu
See accepted insurances
Accepting New Patients
Offers Telehealth

Henry Xiong is a Hematologist Oncology specialist and an Oncologist in Fort Worth, Texas. Dr. Xiong is rated as an Advanced provider by MediFind in the treatment of Ovarian Cancer. His top areas of expertise are Fibrolamellar Carcinoma, Liver Cancer, Colorectal Cancer, and Familial Colorectal Cancer. Dr. Xiong is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Schiller's expertise for a condition
ConditionClose
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile